Lifecome Biochemistry Co.,Ltd. (002868.SZ)
CNY 15.88
(-2.87%)
CNY 15.88
(-2.87%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.96 Billion CNY | 58.49% |
| 2022 | 1.23 Billion CNY | -1.47% |
| 2021 | 1.25 Billion CNY | 29.4% |
| 2020 | 972.5 Million CNY | -3.72% |
| 2019 | 1.01 Billion CNY | 25.88% |
| 2018 | 802.41 Million CNY | 6.11% |
| 2017 | 756.24 Million CNY | 104.03% |
| 2016 | 370.65 Million CNY | -5.57% |
| 2015 | 392.51 Million CNY | 0.62% |
| 2014 | 390.09 Million CNY | -1.46% |
| 2013 | 395.87 Million CNY | 6.6% |
| 2012 | 371.36 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 1.7 Billion CNY | -3.72% |
| 2024 Q2 | 1.76 Billion CNY | -9.59% |
| 2024 Q1 | 1.95 Billion CNY | -0.59% |
| 2023 Q4 | 1.96 Billion CNY | 14.19% |
| 2023 Q1 | 1.17 Billion CNY | -5.11% |
| 2023 FY | 1.96 Billion CNY | 58.49% |
| 2023 Q2 | 1.38 Billion CNY | 17.57% |
| 2023 Q3 | 1.72 Billion CNY | 24.4% |
| 2022 Q3 | 1.26 Billion CNY | 2.21% |
| 2022 Q2 | 1.23 Billion CNY | 0.52% |
| 2022 FY | 1.23 Billion CNY | -1.47% |
| 2022 Q1 | 1.23 Billion CNY | -2.0% |
| 2022 Q4 | 1.23 Billion CNY | -2.14% |
| 2021 Q2 | 999.21 Million CNY | -0.12% |
| 2021 Q4 | 1.25 Billion CNY | 5.01% |
| 2021 FY | 1.25 Billion CNY | 29.4% |
| 2021 Q1 | 1 Billion CNY | 2.87% |
| 2021 Q3 | 1.19 Billion CNY | 19.93% |
| 2020 FY | 972.5 Million CNY | -3.72% |
| 2020 Q4 | 972.5 Million CNY | 0.56% |
| 2020 Q3 | 967.09 Million CNY | 3.02% |
| 2020 Q2 | 938.73 Million CNY | -1.57% |
| 2020 Q1 | 953.75 Million CNY | -5.57% |
| 2019 Q3 | 894.55 Million CNY | 9.38% |
| 2019 FY | 1.01 Billion CNY | 25.88% |
| 2019 Q2 | 817.85 Million CNY | 2.38% |
| 2019 Q1 | 798.88 Million CNY | -0.44% |
| 2019 Q4 | 1.01 Billion CNY | 12.91% |
| 2018 Q1 | 761.92 Million CNY | 0.75% |
| 2018 Q3 | 774.65 Million CNY | 2.23% |
| 2018 FY | 802.41 Million CNY | 6.11% |
| 2018 Q4 | 802.41 Million CNY | 3.58% |
| 2018 Q2 | 757.78 Million CNY | -0.54% |
| 2017 Q2 | 708.92 Million CNY | 94.22% |
| 2017 Q4 | 756.24 Million CNY | 2.62% |
| 2017 Q1 | 365.01 Million CNY | -1.52% |
| 2017 FY | 756.24 Million CNY | 104.03% |
| 2017 Q3 | 736.92 Million CNY | 3.95% |
| 2016 Q4 | 370.65 Million CNY | 0.0% |
| 2016 Q1 | - CNY | 0.0% |
| 2016 FY | 370.65 Million CNY | -5.57% |
| 2015 FY | 392.51 Million CNY | 0.62% |
| 2014 FY | 390.09 Million CNY | -1.46% |
| 2013 FY | 395.87 Million CNY | 6.6% |
| 2012 FY | 371.36 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Beijing Scitop Bio-tech Co., Ltd. | 1.81 Billion CNY | -8.558% |
| Chengdu Kanghua Biological Products Co., Ltd. | 4.2 Billion CNY | 53.317% |
| NanHua Bio-medicine Co., Ltd | 771.38 Million CNY | -154.739% |
| Shandong Sito Bio-technology Co., Ltd. | 3.24 Billion CNY | 39.356% |
| Porton Pharma Solutions Ltd. | 9.38 Billion CNY | 79.06% |
| Zhejiang Wecome Pharmaceutical Company Limited | 2.04 Billion CNY | 3.988% |
| Guangdong VTR Bio-Tech Co., Ltd. | 3.09 Billion CNY | 36.509% |